Change in the reportable segment name to the Metabolomics Business
First written in FY2019-Q2. 9 of 15 entries say "Restated". Latest entry: 2026-08-07.
No other company in this theme has enough history to compare yet.
- FY2026-H1ReframedAnnual report
「From the interim period of the current consolidated fiscal year, the Company changed its reportable segments from the former two segments, the Advanced R&D Support Business and Healthcare Solutions Business, to a single segment, the Contract Metabolome Analysis Services Business.」
The Company changed its reportable segment classification from the former two-segment structure to a single segment, the Contract Metabolome Analysis Services Business. - FY2023-Q3RestatedAnnual report
「Reportable segments Advanced R&D Support Business Healthcare Solutions Business」
The Company continues to use the reportable segment structure comprising the Advanced R&D Support Business and Healthcare Solutions Business. - FY2023-Q1RestatedAnnual report
「In this business segment, high-sensitivity comprehensive analysis services remained firm both in Japan and overseas, and sales increased substantially, mainly in the academia sector.」
The Company continues to use the reportable segment structure comprising the Advanced R&D Support Business and Healthcare Solutions Business. - FY2022-Q3RestatedAnnual report
「From the first quarter of the consolidated fiscal year, the Company changed its reportable segments, in line with changes in its management policies and strategy, from the former Metabolomics Business and Biomarker Business to the Advanced R&D Support Business and Healthcare Solutions Business.」
The new two-segment structure introduced from the first quarter of FY2022 continues to be used. - FY2022-Q2RestatedAnnual report
「From the first quarter of the consolidated fiscal year, the Company changed its reportable segments, in line with changes in its management policies and strategy, from the former Metabolomics Business and Biomarker Business to the Advanced R&D Support Business and Healthcare Solutions Business.」
The new two-segment structure introduced from the first quarter of FY2022 continues to be used. - FY2022-Q1AdvancedAnnual report
「From the first quarter of the current consolidated fiscal year, the Company changed its reportable segments, in line with changes in its management policies and strategy, from the former Metabolomics Business and Biomarker Business to the Advanced R&D Support Business and Healthcare Solutions Business.」
The new two-segment business classification presented in FY2021 was actually introduced as the reportable segment structure from the first quarter of FY2022. - FY2021ReframedAnnual report
「In addition, from the fiscal year ending June 2022 onward, the Metabolomics Business and new contract analysis services will constitute the Advanced R&D Support Business segment, while the Biomarker Business and new businesses will constitute the Healthcare Solutions Business segment.」
The Company indicated plans to redefine the former reportable segments, the Metabolomics Business and the Biomarker Business, into two new segments from the fiscal year ending June 2022 onward. - FY2021-Q2RestatedAnnual report
「Metabolomics business」
The Company continues to use the classifications of the Metabolomics Business and the Biomarker Business adopted after the reportable segment name change. - FY2020RestatedAnnual report
「The Group operates its business on the basis of CE-MS metabolome analysis technology and, taking into account its services, products and revenue model, defines its reportable segments as the Metabolomics Business and the Biomarker Business.」
The Company continues to classify its reportable segments as the Metabolomics Business and the Biomarker Business. - FY2020-Q2RestatedAnnual report
「In this business segment, the Group continued to conduct active promotional activities, as in the previous fiscal year, worked to expand orders for large projects in the pharmaceutical, food, chemical and other fields, and reviewed its sales strategy and worked to strengthen its sales organisation.」
The reportable segment continues to be described as the Metabolomics Business, retaining the classification adopted after the name change. - FY2019RestatedAnnual report
「From the third quarter of the consolidated fiscal year, the former reportable segment, the Metabolome Analysis Business, was renamed the Metabolomics Business.」
The change in the reportable segment name continues to be disclosed. - FY2019-Q3RestatedAnnual report
「In addition, from the third quarter of the consolidated fiscal year, the former reportable segment, the Metabolome Analysis Business, was renamed the Metabolomics Business.」
The change in the reportable segment name continues to be disclosed, and the Company stated that there was no impact on segment information. - FY2019-Q2First statedAnnual report
「From the third quarter of the current consolidated fiscal year, the former reportable segment, the Metabolome Analysis Business, was renamed the Metabolomics Business.」
The reportable segment was renamed from the third quarter of the current consolidated fiscal year. The Company stated that there was no impact on segment information.